Stocks Hold Near Session Highs; FedEx Bounces Back
at Investor's Business Daily - Thu Dec 18, 1:52PM CST
Stocks held steady and near session highs heading into the final hour of trading Thursday. The Nasdaq led in the stock market today, climbing 1.7%. The S&P 500 and Dow Jones industrial average each picked up 1.6%. Volume on the NYSE and Nasdaq was...
FDX: 176.42 (-0.52), BIIB: 340.89 (+5.13), INSY: 41.52 (+0.51), CTAS: 79.86 (+0.22)
Will INSYS (INSY) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 8:28AM CST
Will INSYS (INSY) Continue to Surge Higher?
INSY: 41.52 (+0.51)
RedHill submits MAA for ondansetron
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 11:38AM CST
INSY: 41.52 (+0.51), TSRO: 36.80 (+0.57), HRTX: 9.75 (+0.02), RDHL: 12.22 (-0.13), GWPH: 68.08 (+1.82), OPK: 9.63 (+0.21), GALE: 1.49 (-0.02)
Insys Therapeutics Receives FDA Orphan Drug Designation for Liposome Entrapped Paclitaxel as a Potential Treatment for Gastric Cancer
Marketwired - Tue Dec 09, 6:00AM CST
Insys Therapeutics, Inc. (NASDAQ: INSY), a specialty pharmaceutical company that is developing and commercializing innovative drugs and novel drug delivery systems, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to its Liposome Entrapped Paclitaxel Easy to Use ("LEP-ETU"
INSY: 41.52 (+0.51)
Why GW Pharmaceuticals Is Currently The Only Game In Town For A Cannabis Play
Nick Cox - at Seeking Alpha - Mon Dec 08, 10:59AM CST
INSY: 41.52 (+0.51), GWPH: 68.08 (+1.82)
Novus Becomes an Insurance Leader as MMJ Market Approaches Tipping Point
ACCESSWIRE - Mon Dec 08, 9:21AM CST
WHITEFISH, MT / ACCESSWIRE / December 8, 2014 / A unique company in the MMJ space today that is focused on the medical insurance side of the business is Novus Acquisition & Development (OTC: NDEV). Novus provides health insurance and insurance related solutions to the growing wellness and MMJ markets using an innovative cost-saving provider network model that is administered via their wholly-owned Novus Medical Group subsidiary's Novus MedPlan. The timely rollout of the Novus MedPlan in states where MMJ is legal, which gives patients access to considerable discounts on MMJ products for a modest subscriber fee of under $20 a month, was recently highlighted in Forbes as the number one pick, taking the top slot out of a list of the eight hottest publicly traded companies to draw the interest of investors in this rapidly emerging sector.
CARA: 9.78 (+0.02), INSY: 41.52 (+0.51), GWPH: 68.08 (+1.82)
Meridian Bioscience: A Strong Sell on Dismal Q4, Competition - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 12:40PM CST
On Dec 2, 2014, Zacks Investment Research downgraded diagnostic test-kit maker Meridian Bioscience Inc. (VIVO) to a Zacks Rank #5 (Strong Sell).
ICUI: 83.38 (+1.63), INSY: 41.52 (+0.51), VIVO: 16.68 (-0.02), OSUR: 10.26 (+0.25)
Parallel Comparison Analyses Confirm That Insys Therapeutics' Synthetic CBD Is Identical in Chemical Structure to Plant-Derived CBD
Marketwired - Thu Dec 04, 6:02AM CST
Independent comparison analyses have found that cannabidiol (CBD) synthetically produced by Insys Therapeutics, Inc. (NASDAQ: INSY) is chemically identical to plant-derived CBD. Analyses were conducted independently by Insys and the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health.
INSY: 41.52 (+0.51)
Insys' promotion of narcotic continues to draw attention
Seeking Alpha - at Seeking Alpha - Tue Dec 02, 12:38PM CST
INSY: 41.52 (+0.51)
Insys' Cannabidiol Gets another Orphan Drug Designation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 25, 9:40AM CST
Insys Therapeutics, Inc.'s (INSY) pharmaceutical cannabidiol (CBD) candidate received orphan drug designation from the FDA for the treatment of pediatric schizophrenia.
IPXL: 31.32 (+0.26), AGN: 210.12 (+0.95), LCI: 42.29 (+1.79), INSY: 41.52 (+0.51)
Insys cannabidiol tagged an Orphan Drug for pediatric schizophrenia
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 12:10PM CST
INSY: 41.52 (+0.51)
3 Fast-Growing Biotech Stocks To Buy in December
Todd Campbell, The Motley Fool - Motley Fool - Mon Nov 24, 9:46AM CST
Year end is coming up quickly, and that has investors pouring over portfolios, dissecting financial reports, and considering names to own heading into 2015. With that in mind, read on to learn why I think these three biotech stocks may prove...
INSY: 41.52 (+0.51), EBS: 27.64 (+1.28), CBST: 100.29 (-0.09)
Cardica (CRDC) in Focus: Stock Moves Up 8.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 24, 7:37AM CST
Cardica Inc. (CRDC) was a big mover last session, as the company saw its shares rise nearly 9% on the day.
ICUI: 83.38 (+1.63), INSY: 41.52 (+0.51), GWPH: 68.08 (+1.82), CRDC: 0.69 (unch)
Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol as a Potential Treatment for Pediatric Schizophrenia
Marketwired - Mon Nov 24, 6:01AM CST
Insys Therapeutics, Inc. (NASDAQ: INSY), a specialty pharmaceutical company that is developing and commercializing innovative drugs and novel drug delivery systems, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to its pharmaceutical cannabidiol (CBD) candidate for the treatment of pediatric schizophrenia. This marks the fifth ODD for the company's CBD program.
INSY: 41.52 (+0.51)
The Real Reason Marijuana is a Dangerous Investment
Sean Williams, The Motley Fool - Motley Fool - Sun Nov 23, 11:18AM CST
Source: Flickr user Isabel Mancera. When it comes to hot investing opportunities , few are likely to raise the eyebrows of traders these days more than marijuana. Estimates as to how big the legal marijuana market could eventually become vary...
INSY: 41.52 (+0.51), GWPH: 68.08 (+1.82)
Could Warren Buffett's Investing Strategy Include Marijuana Stocks?
Sean Williams, The Motley Fool - Motley Fool - Sat Nov 22, 11:39AM CST
Few investors are as highly regarded -- and as successful -- as the Oracle of Omaha, Warren Buffett. In just over six decades, Buffett's investing strategy has grown his wealth from about $10,000 to more than $71 billion. Not too shabby, right? ...
INSY: 41.52 (+0.51), GWPH: 68.08 (+1.82)
Insider Trading Alert - INSY, LNKD And IMPV Traded By Insiders
at The Street - Fri Nov 21, 9:30AM CST
Stocks with insider trader activity include INSY, LNKD and IMPV
INSY: 41.52 (+0.51), LNKD: 231.83 (+0.34), IMPV: 51.87 (+1.18)
3 Healthcare Stocks Short-Sellers Are Wrong About
Motley Fool Staff - Motley Fool - Fri Nov 21, 9:27AM CST
Short-sellers have been piling into a number of healthcare stocks lately. This trend lends itself well to the possibility of exploiting a so-called "short squeeze", where share prices rise as short-sellers scramble to cover their positions. We asked...
JNJ: 104.59 (+0.31), INSY: 41.52 (+0.51), GERN: 3.06 (+0.05), RMTI: 8.41 (-0.07)
Insys Therapeutics to Present at 26th Annual Piper Jaffray Healthcare Conference
Marketwired - Wed Nov 19, 4:16PM CST
Insys Therapeutics, Inc. (NASDAQ: INSY), a specialty pharmaceutical company that is developing and commercializing innovative drugs and novel drug delivery systems, today announced that Michael L. Babich, President and Chief Executive Officer, and Darryl Baker, Chief Financial Officer, will present at the 26th Annual Piper Jaffray Healthcare Conference as follows:
INSY: 41.52 (+0.51)
Weakness Seen in Vascular Solutions (VASC): Stock Plunges 22.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 7:52AM CST
Vascular Solutions has been witnessing a negative trend in its current year earnings estimate and its share price has showed a sharp decline in the last 24 hours
ICUI: 83.38 (+1.63), INSY: 41.52 (+0.51), GWPH: 68.08 (+1.82), VASC: 27.30 (+0.71)